Clinical trials
EGFR Activating Mutation clinical trials
Below are recruiting egfr activating mutation clinical trials, each written for real people, not researchers. We’re tracking 109 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06674343RecruitingPhase 3
Furmonertinib for advanced lung cancer with EGFR mutations
This trial tests a higher dose of furmonertinib (160mg) as a first treatment for advanced non-small cell lung cancer that has specific EGFR mutations (19Del or L858R). It aims to see if this drug can help shrink tumors and delay disease progression.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07538804RecruitingPhase 1/Phase 2
Testing ANS02 for EGFR-Mutated Lung Cancer
This trial tests a new drug called ANS02 in people with non-small cell lung cancer (a common type of lung cancer) that has a specific genetic change called an EGFR mutation. The drug is designed to target and slow cancer growth in people with this mutation.
Fairfax, VirginiaAges 18 years+ - NCT07117890RecruitingPhase 2
Sunvozertinib for untreated NSCLC with EGFR rare mutations
This trial tests a drug called sunvozertinib in people with advanced non-small cell lung cancer (NSCLC) that has not been treated yet. It is for those who have certain uncommon changes in the EGFR gene. The drug may shrink tumors or stop them from growing.
ShanghaiAges 18 years+ - NCT07089641RecruitingPhase 1
Testing a new pill for EGFR-mutated glioblastoma
This trial tests a new pill called ERAS-801 for people with a type of brain tumor (glioblastoma) that has a specific change in the EGFR gene. The study is for patients whose tumor has come back after treatment, or for those 70 or older who are newly diagnosed.
Los Angeles, CaliforniaAges 18 years+ - NCT07195695RecruitingPhase 3
Zongertinib after surgery for HER2-mutated lung cancer
This trial tests a new pill, zongertinib, against standard of care for people with early-stage (II–IIIB) non-small cell lung cancer that has a specific HER2 mutation in the tyrosine kinase domain. The goal is to see if zongertinib can prevent the cancer from coming back after complete surgical removal.
Fresno, CaliforniaAges 18 years+ - NCT06970639RecruitingPhase 3
Study comparing new targeted drug plus chemo vs osimertinib for lung cancer with brain tumors
This trial tests a new targeted therapy called furmonertinib combined with chemotherapy against the current standard osimertinib for people with a specific type of non-small cell lung cancer (NSCLC) that has spread to the brain. It aims to find a better treatment option for patients whose cancer cells have a common EGFR mutation.
Guangdong, GuangzhouAges 18 years+ - NCT06706076RecruitingPhase 1/Phase 2
Experimental pill for lung cancer with EGFR or HER2 changes
This study tests an experimental pill that targets cancer cells with certain gene changes (EGFR or HER2). It may help shrink tumors or slow the cancer's growth in people with advanced non-small cell lung cancer.
Phoenix, ArizonaAges 18 years+ - NCT07392658RecruitingPhase 2
Amivantamab plus chemo for EGFR-mutated lung cancer
This trial tests whether the drug amivantamab combined with a single chemotherapy drug can help people with advanced non-small cell lung cancer that has a specific EGFR gene mutation (exon20 insertion). It is for people who cannot safely receive standard platinum-based chemotherapy.
Roma, Roma (RM)Ages 18–99 - NCT06192849RecruitingPhase 2
Furmonertinib after surgery for EGFR 20 insertion lung cancer
This trial tests a targeted pill (furmonertinib) to prevent your lung cancer from coming back after surgery. It is for people with a certain genetic change in their tumor (EGFR exon 20 insertion) and stage IB, II, or IIIA disease.
Chengdu, SichuanAges 18 years+ - NCT06226857RecruitingPhase 3
Anti-EGFR for left-sided, RAS wild-type metastatic colorectal cancer
This trial tests whether anti-EGFR therapy works better for people with left-sided colorectal cancer that has spread, whose tumors do not have certain gene mutations (RAS wild-type). It is for those who have not yet had treatment for metastatic disease.
MoscowAges 18–99 - NCT06501378RecruitingPhase 2
Brain radiation plus chemotherapy and immunotherapy for lung cancer brain metastases
This trial tests a combination of radiation to the brain plus chemotherapy and immunotherapy (anti-PD-1/PD-L1) for people with newly diagnosed non-small cell lung cancer that has spread to the brain. It is for those whose tumors do not have common driver mutations and whose brain metastases are causing symptoms.
ShanghaiAges 18 years+ - NCT06043817RecruitingPhase 1/Phase 2
Study of STX-721 for advanced lung cancer with EGFR or HER2 changes
This trial tests a new drug, STX-721, for people with advanced non-small cell lung cancer that has a specific genetic change (EGFR or HER2 exon 20 insertion). The study aims to see if the drug is safe and effective.
Duarte, CaliforniaAges 18 years+ - NCT07462377RecruitingPhase 1
Testing EPI-326 for EGFR-mutant lung and head & neck cancers
This trial tests a new drug, EPI-326, in people with advanced lung or head & neck cancers that have certain EGFR changes. The goal is to see if it is safe and may help shrink the cancer.
Los Angeles, CaliforniaAges 18 years+
Hear when a new EGFR Activating Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for egfr activating mutation?
- Yes. Clin2 currently lists 109 recruiting egfr activating mutation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a egfr activating mutation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a egfr activating mutation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.